Robert W. Baird Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $54.00
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) had its price target reduced by research analysts at Robert W. Baird from $75.00 to $54.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an “outperform” rating on the stock. A number of other research analysts also recently issued reports on the […]
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) had its price target reduced by research analysts at Robert W. Baird from $75.00 to $54.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an “outperform” rating on the stock. A number of other research analysts also recently issued reports on the […]
